PHASE I/II STUDY OF IMMUNIZATION WITH MHC CLASS I MATCHED ALLOGENEIC HUMAN PROSTATIC CARCINOMA CELLS ENGINEERED TO SECRETE INTERLEUKIN-2 AND INTERFERON-GAMMA
OBJECTIVES: I. Evaluate the safety of immunization with HLA class I-matched allogeneic human
prostate carcinoma cells genetically engineered to secrete interleukin-2 and interferon
gamma in patients with prostate carcinoma. II. Evaluate the antitumor effects of this
treatment as assessed by post-therapy declines in PSA. III. Evaluate the induction of
cellular and humoral immunity in vivo with this treatment.
OUTLINE: Tumor Cell Vaccine Therapy. Immunization with irradiated, MHC class I-matched
allogeneic human prostate carcinoma cells, LNCaP cells, engineered to secrete approximately
58 ng/24 hr/million cells of interleukin-2 (IL-2) and approximately 0.72 U/24 hr/million
cells of interferon gamma (IFN-G).
PROJECTED ACCRUAL: Up to 12 patients will be entered on the Phase I study; accrual will
continue to a total of 25 patients treated at the MTD (Phase II). Accrual is expected to
require 2 years.
Primary Purpose: Treatment
Susan Slovin, MD, PhD
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
|Memorial Sloan-Kettering Cancer Center||New York, New York 10021|